Cited 1 times in
Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박성하 | - |
dc.date.accessioned | 2019-03-15T02:31:56Z | - |
dc.date.available | 2019-03-15T02:31:56Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/167561 | - |
dc.description.abstract | Recent changes in American and European guidelines on the management of arterial hypertension have caused a considerable shift in the landscape of hypertension management. The 2017 American College of Cardiology/American Heart Association/American Society of Hypertension guideline recommends an office visit blood pressure (BP) > 130/80 mmHg as the new threshold for diagnosis of hypertension, and states that the treatment goal for all hypertensive patients should be lowered to < 130/80 mmHg. In contrast, the 2018 European guideline maintains the diagnostic threshold of hypertension at 140/90 mmHg. However, despite their differences in thresholds for diagnosis of hypertension, both guidelines are in agreement that treatment should be considered in patients with BPs in the range of 130 to 139/80 to 89 mmHg if they have high cardiovascular risk. The results from the Systolic Blood Pressure Intervention Trial (SPRINT) study and recent meta-analyses suggest that BP lowering with antihypertensive treatment may be beneficial in reducing cardiovascular event rates in subjects with high-normal BP or stage 1 hypertension according to the new American guideline. However, intensive BP lowering is associated with increased incidence of treatment-associated adverse events, and evidence suggests that BP lowering below 120/70 mmHg increases the risk of cardiovascular events. In this review, we discuss the evidence supporting antihypertensive treatment in subjects with high-normal BP and discuss the specific subgroup of subjects that might benefit from BP lowering. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association of Internal Medicine | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sungha Park | - |
dc.identifier.doi | 10.3904/kjim.2018.382 | - |
dc.contributor.localId | A01512 | - |
dc.relation.journalcode | J02883 | - |
dc.identifier.eissn | 2005-6648 | - |
dc.identifier.pmid | 30612417 | - |
dc.subject.keyword | Blood pressure | - |
dc.subject.keyword | Cardiovascular diseases | - |
dc.subject.keyword | Hypertension | - |
dc.subject.keyword | Treatment target | - |
dc.contributor.alternativeName | Park, Sung Ha | - |
dc.contributor.affiliatedAuthor | 박성하 | - |
dc.citation.volume | 34 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 44 | - |
dc.citation.endPage | 49 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.34(1) : 44-49, 2019 | - |
dc.identifier.rimsid | 47009 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.